Abstract
The impact of tipranavir plasma levels (TPV C min) on virological response was examined in 36 antiretroviral-experienced HIV-infected individuals. Although TPV C min did not predict outcome in patients with less than five or more than eight baseline TPV-associated resistance mutations, TPV C min values were greater in responders than in nonresponders with five to seven baseline TPV-associated resistance mutations (38.8 vs. 13.8 g/ml, p = 0.017). Thus, therapeutic drug monitoring might be helpful in ensuring a viral response in this subset of patients.
Get full access to this article
View all access options for this article.